Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06591806 · ClinicalTrials.gov registry record
An Observational Study in Children and Adults With Stargardt Disease
A clinical trial of Stargardt Disease, sponsored by AAVantgarde Bio Srl.
- Recruiting
- Registry status
- 80
- Enrollment target
- 2
- Study locations
NCT06591806: Recruiting study of Stargardt Disease, sponsored by AAVantgarde Bio Srl.
NCT06591806 is a study of Stargardt Disease that is actively recruiting participants, run by AAVantgarde Bio Srl. The registered enrollment target is 80 participants, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06591806, a study of Stargardt Disease, is actively recruiting participants, sponsored by AAVantgarde Bio Srl.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
This multicenter, prospective, longitudinal, observational study in approximately 80 subjects with Stargardt disease secondary to biallelic mutations in the ABCA4 gene (STGD1) aims to evaluate prognostic factors of disease progression, and to further characterize the patient population for future clinical studies.
Conditions Studied
Study Locations (2)
Texas
- Retina Foundation of the Southwest - Dallas
Other
- Oslo University hospital Ullevål - Oslo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2027-06-30 |
What NCT06591806 shows while recruiting
NCT06591806 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, roughly in line with the 86-participant average among 16 other Stargardt Disease trials with a reported enrollment target.
The record links to 1 condition, with Stargardt Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06591806 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06591806 about?
NCT06591806 is a clinical study titled "An Observational Study in Children and Adults With Stargardt Disease". This multicenter, prospective, longitudinal, observational study in approximately 80 subjects with Stargardt disease secondary to biallelic mutations in the ABCA4 gene (STGD1) aims to evaluate prognostic factors of disease progression, and to further characterize the patient population for future cl...
What is the current status of trial NCT06591806?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2024-05-01. Estimated completion is 2027-06-30.
What conditions does trial NCT06591806 study?
This clinical trial studies the following conditions: Stargardt Disease.
Who is sponsoring clinical trial NCT06591806?
This trial is sponsored by AAVantgarde Bio Srl, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06591806 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06591806's enrollment target sits among peer trials
80 5th of 16 higher than 12 of 16 other Stargardt Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stargardt Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
RECRUITING
-
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
RECRUITING · Phase 2
-
Stem Cell Ophthalmology Treatment Study II
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI